Search

Displaying results 3441 - 3450 of 7706 in total
  1. Drug

    Tozasertib

    go.drugbank.com/drugs/DB19675
    Investigational

    Tozasertib has a monoisotopic molecular weight of 464.21 Da. … Tozasertib is under investigation in clinical trial NCT02532868 (A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)).

  2. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. Thymectacin is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a c...

  3. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    Nevadistinel has a monoisotopic molecular weight of 274.13 Da. … The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist.

  4. Drug

    Aluminum zirconium pentachlorohydrex gly

    go.drugbank.com/drugs/DB11277
    ApprovedWithdrawn

    Aluminum zirconium pentachlorohydrex gly, or Aluminum Zirconium Tetrachlorohydrex Glycine, is commonly used as an antiperspirant in many deodorant products.

  5. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

  6. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  7. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  8. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).

    Products: BROTIZOLAM DOC GENERICI
  9. Drug

    Solcitinib

    go.drugbank.com/drugs/DB19856
    Investigational

    Solcitinib has a monoisotopic molecular weight of 389.19 Da. … Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184).

  10. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.